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Summary Suppressor gene loci involved in the development of hepatocellular carcinoma (HCC) have not
been fully identified. The aim of this study was to look for consistent allele loss, or loss of heterozygosity
(LOH), in HCC which might represent such gene loci. We have prepared DNA from tumour and non-tumour
material from 16 patients with HCC (nine with and seven without liver cirrhosis). Tumour DNA was
compared with non-tumour DNA by Southern analysis performed with a panel of 22 probes recognising
restriction fragment length polymorphisms assigned to chromosomes 1, 4, 5, 7, 9, 11, 12, 13, 14, 16, 17, 18 and
20. Non-tumour DNA from five of the seven patients with HCC without cirrhosis was heterozygous with the
probe Lambda MS8 (5q35-qter), and in all five there was LOH in tumour DNA. Probes for other regions of
chromosome 5 have as yet shown no LOH in this group of patients. Cirrhotic HCC patients exhibited LOH
on chromosomes lq and 5p but not in the region 5q35-qter. Both groups of HCC showed LOH on
chromosome l7pl3. Screening with other probes has not shown any consistent LOH in either group as yet. A
comparison of LOH on chromosome 5 in seven patients with colorectal metastasis in the liver showed a
different pattern, which suggests that the proposed tumour suppressor gene locus for HCC without cirrhosis
on chromosome 5 appears to be distinct from the familial adenomatous polyposis coli gene.
Hepatocellular carcinoma (HCC) is a major cause of death
from malignancy in the world, with a particularly high
incidence in the Far East and Africa where hepatitis B virus
(HBV) infection, established as an aetiological agent, is com-
mon. In Western countries the incidence is lower but increas-
ing. Most HCC are beyond radical resection when detected,
and all other forms of the currently available therapies are
rarely beneficial. For these reasons the cellular and molecular
changes leading to HCC demand study, with a view to
identification of patients at particular risk, earlier detection
of tumours and, in the long-term, successful therapy.
In most tumours carcinogenesis is the result of an interac-
tion between genetic and environmental factors, and appears
to be a multistep process. Several mutations may be neces-
sary and in broad terms two interacting mechanisms seem to
be involved: oncogene activation or mutation, and loss of
tumour suppressor factors. Mutant oncogenes introduced
into cultured cells are capable of inducing malignant trans-
formation. In patients with tumours, mutation of an onco-
gene may allow production of proteins which perpetuate
proliferation. Evidence is accumulating now that excess pro-
liferation is opposed by the products of tumour suppressor
genes, and that these are at least as important as oncogenes
in carcinogenesis. Their presence was predicted by Knudson's
model for sporadic and inherited forms of retinoblastoma
(Knudson, 1971). The gene involved in retinoblastoma has
now been identified and the gene product characterised
(Friend et al., 1986; Lee et al., 1987). Loss of tumour sup-
pressor has now been implicated in Wilms' tumour (Rose et
al., 1990), acoustic neuroma (Seizinger et al., 1986) and also
carcinomas of the colon (Fearon et al., 1990; Kinzler et al.,
1991), lung (Kok et al., 1987) and breast (Mackay et al.,
1988).
For the common tumours such as carcinomas of the colon,
breast and lung, the evidence for loss of tumour suppressor
genes has accumulated from the demonstration of a consis-
tent loss of a region of genomic DNA in tumour tissue
('allele loss') when compared with the individual's normal
DNA. Allele loss, or loss of heterozygosity (LOH), on
chromosomes 5,17 and 18 has been found in colonic car-
cinoma (Vogelstein et al., 1988). Introduction of a normal
chromosome 5 or 18 into this tumour, in vitro, suppresses
tumorigenicity (Tanaka et al., 1991). Two candidate colon
tumour suppressor genes, DCC and MCC on chromosomes
18 and 5 respectively, have been identified (Fearon et al.,
1990; Kinzler et al., 1991).
Most HCC are associated with chronic HBV infection. The
HBV genome is integrated into the host DNA and many
studies have detailed sites of integration looking for a consis-
tent pattern and/or changes which might activate oncogenes.
No consistent pattern has been found (Di Bisceglie, 1989).
Loss of specific segments of chromosomal DNA, however,
has been shown including regions on chromosomes 4, 11 and
13 (Buetow et al., 1989; Wang et al., 1986) and these may be
the sites of tumour suppressor genes. In HCC without HBV
infection, which is more common in Western countries, little
is known about the genetic changes. They usually present
without liver cirrhosis and have a different prognosis. There-
fore we performed this study to establish whether there are
different consistent patterns of allele loss in HCC with or
without liver cirrhosis.
Materials and methods
Patients andbiopsies
We have studied 16 patients with HCC (nine with and seven
without liver cirrhosis) and seven patients with liver metas-
tases from colorectal primary tumours. Of the seven patients
with HCC without cirrhosis, six were HBV negative and one
HBV positive. All nine patients with HCC and cirrhosis were
HBV positive. All these patients had their tumours localised
to the liver with no extrahepatic spread based on pre-
operative imaging and findings at laparotomy. All underwent
either liver resection or liver transplantation. None of these
patients had a tumour of the fibrolamellar type. Surgical
biopsies from the tumour and non-tumour liver tissue were
snap frozen in liquid nitrogen at the time of liver resection.
Lymphocytes from peripheral blood obtained preoperatively
and before any blood transfusion were also used as a source
of normal DNA. Tissue was stored at - 70°C until DNA
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extraction. None of the patients received chemotherapy or
radiotherapy before surgery and tumour samples were exam-
ined histologically to confirm the type of tumour present.
Patient's viral hepatitis status was determined by analysis
of serum for hepatitis B markers and by Southern analysis of
liver tissue DNA using the HBV genome probe pEco63.
DNA extraction and hybridisation
DNA was prepared from blood and tissue samples by stan-
dard phenol/chloroform methods (Sambrook et al., 1989).
Samples were digested with the appropriate restriction endo-
nuclease and were size fractionated by electrophoresis
through 0.6-0.9% agarose gels. The DNA was transferred to
Hybond-N hybridisation filters (Amersham) according to the
manufacturer's specifications. DNA probes were radiolab-
elled with alpha-32P-dCTP (3,000Cimol ') by the random
hexanucleotide primer method (Feinberg & Vogelstein, 1983)
to a high specific activity. Hybridisations were performed at
650C in 1% SDS, 1 M NaCl and 5% dextran sulphate (W:V)
for 16-24 h. Filters were washed to stringency of 2 x SSC
1% SDS (W:V) at 640C and were autoradiographed at
- 70°C using Fuji: RX-L X-ray film.
The detection of chromosomal DNA loss depends upon
demonstrating a difference in restriction fragment length
polymorphism (RFLP) between tumour and non-tumour
('normal') DNA. Most of the probes used were selected
because they are hypervariable, that is the majority of indi-
viduals will be heterozygous and hence informative at these
loci (Wong et al., 1987). A deletion in the region studied may
then be seen as a loss of a band (or loss of intensity of a
band). In this study we used 22 probes for chromosomes
1, 4, 5, 7, 9, 11, 12, 13, 14, 16, 17, 18 and 20 and of these 12
were hypervariable (Table I). The remainder were chosen
because they were shown to be of importance in studies of
other tumours. The analyses showing a partial or complete
loss of a band are reported in this study as showing allele
loss, while gene rearrangements with partial or complete gain
of a band in tumours were not included.
Results
Table I shows the overall pattern of allele loss, or loss of
heterozygosity (LOH), in DNA from 16 HCC compared to
non-tumour DNA. The analyses showed an informative pat-
tern in 186 of 268 Southern blots (heterozygosity: 69.4%).
Overall LOH was present in 30/186 (16.1%). Figure 1 shows
representative examples of LOH.
In the seven patients with HCC without liver cirrhosis a
high frequency of LOH only occurred in the regions 5q35-
qter and 17pl3 (Tables I and II). The probe for the terminal
region of long arm of chromosome 5 (Lambda MS8, 5q35-
qter) was informative in five cases and all showed LOH. Of
the four patients informative with the probe pl44-D6 for the
short arm of chromosome 17 (17pl3) three showed LOH.
In the nine patients with HCC and liver cirrhosis LOH was
found on chromosomes Iq, Sp and 17p in at least half of the
informative cases (Tables I and II). Out of six informative
patients five showed LOH at 17pl3 by the probe pl44.D6.
Five cases in this group were heterozygous with the probe
Lambda MS8 (5q35-qter), but none of them exhibited LOH.
Instead, a single patient (No. 6, Table II) showed LOH on
5q21-22, but was non-informative for Lambda MS8 (5q35-
qter).
Previous work on colorectal adenomas and carcinomas has
shown that the chromosome 5 region (5q21-22) encompas-
sing the familial adenomatous polyposis coli (APC) gene is
deleted in inherited and sporadic colorectal cancer (Miyaki et
al., 1990). For this reason we compared the pattern of allele
loss in non-cirrhotic HCC with that of colorectal liver secon-
daries using various probes for chromosome 5q (Figure 2).
Table II shows that patients with non-cirrhotic HCC had no
allele loss when screened with probes mapped to regions of
the chromosome other than 5q35-qter. On the other hand
only two of five patients with colorectal liver metastases
(informative with probe lambda MS8) showed allele loss in
that region, but the majority of these patients showed allele
loss with probes from 5q21-22, the region of the chromo-
some associated with colorectal cancer.
Table I Loss ofchromosomal heterozygosity in human hepatocellular carcinoma
HCC without HCC with
Chromosome Probe Locus Enzyme Cirrhosis (n = 7) Cirrhosis (n = 9) Reference
AMSI lp33-35 Hinfl 1/5* 0/8 Wong et al., 1987
1 PB3 1q21-23 MspI 0/2 1/2 Scott et al., 1985
AMS32 lq42-43 AluI 0/3 3/5 Wong et al., 1987
4 F47.3 4qll-13 HaeIII 0/4 0/4 Murray et al., 1983
pMS621 5p Hinfl 0/4 3/4 Armour et al., 1990
5 ECB27 5q21 BgIII 0/4 1/4 Vareso et al., 1989
YN5.48 5q21-22 MspI 0/3 1/3 Nakamura et al., 1988a
)AMS8 5q35-qter Hinfl 5/5 0/5 Wong et al., 1987
7 AMS31 7pter-q22 Hinfl 0/4 1/7 Wong et al., 1987
pAXg3 7q31.3-qter Hinfl 0/3 0/7 Wong et al., 1987
9 EFD126.3 9q34 PvuII 0/2 1/4 Nakamura et al., 1987
11 H-ras lIpIS BamHI 0/2 0/3 Krontiris et al., 1985
pMS51 11ql3 HaeIlI 0/4 0/6 Armour et al., 1989
12 AMS43 12q24.3-qter Hinfl 1/5 0/7 Wong et al., 1987
13 pMS626 13q AluI 0/5 0/6 Armour et al., 1990
14 pMS627 14q Alul 0/5 0/5 Armour et al., 1990
16 3'HVR 16pl3.3 PvuII 0/5 0/6 Higgs et al., 1986
pulB1148 16q22.1 TaqI 0/3 0/3 vander Straten et al., 1983
17 p144-D6 17pl3 RsaI 3/4 5/6 Kondoleon et al., 1987 pYNZ.22 17pl3 RsaI 1/5 2/4 Nakamura et al., 1988b
18 pMS440 18q Haelll 0/3 0/2 Armour et al., 1990
20 pMS617 20q AluI 0/2 1/3 Armour et al., 1990
*No. with allele loss; No. of informative cases.ALLELE LOSS IN HCC 1085
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Figure 1 Autoradiographs of Southern hybridisations with MS8
and p144-D6. Patient numbers are indicated above the tracks.
B = blood lymphocyte DNA; N = non-tumour tissue DNA;
T = tumour tissue DNA. No. 2 is HCC with cirrhosis, and nos 9
and 10 are HCC without cirrhosis. All show allele losses in
tumour DNA.
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region of the long arm of chromosome 5 (i.e. 5135-qter) in
patients with non-cirrhotic HCC and the short arm of
chromosome 5 (Sp) in patients with cirrhotic HCC. Patients
with non-cirrhotic HCC showed LOH mainly on chromo-
AAC_ - 1 wt7-A_A A -&._,. LAs_&T 'T" i 1- 2 somes 3q and I/p, wnlue patients with cirrhotic HtUC had
allele loss on chromosomes lq, 5p and 17p. Chromosomes
17p and Iq allele losses are shared with many other tumours
and are likely to represent 'tumour progression' (Sager,
1989). The presence of a tumour suppressor gene locus on
the short arm of chromosome 5 has not been previously
reported and may be important in cirrhotic HCC.
It is interesting that the pattern of chromosomal deletion
in HCC shown so far correlates more on the present or
absence of liver cirrhosis rather than the presence or absence
of HBV infection. Since it was shown that tumours from
patients who are seropositive for markers of HBV infection
contain integrated HBV DNA sequences it has been argued
that the viral genome may be involved in the induction
and/or maintenance of the neoplastic phenotype (Chen et al.,
1988). The role of virally mediated oncogenesis in HCC has
been widely studied, but yet, no conclusive results have
emerged. Therefore it was interesting to find in our study no
absolute differences in LOH pattern between HCC with or
without HBV infection in spite of the differences in the
aetiology and pathology processes. This lends support to the
hypothesis that the development of cirrhosis (with its regen-
erative capacity) rather than the presence of integrated HBV
genome is most important, although the number of patients
studied to date is small. It remains to be seen whether
tumour suppressor gene loss is different in HCC from cir-
Table II Allele loss on chromosome 5 in HCC and colonic metastases in liver
Probes and loci
pMS621 ECB27 YNS.48 Lambda MS8
Patients 5p Sq21 5q21-22 5q35-qter
HCC with cirrhosis
1 1,2 - - 1,2
2 1,(2) - 1,2 _
3 - 1,2 - -
4 - 1,2 - 1,2
5 1,(2) 1,2 1,2 1,2
6 1,(2) (1),2 (1),2
7 nd nd
22 nd - nd 1,2
23 nd - - 1,2
Total no. 6 9 7 9
Heterozygosity 4 4 3 5
Allele loss 3 1 1 0
HCC without cirrhosis
8 1,2 1,2 - 1,(2)
9 - 1,2 - 1,(2)
10 1,2 - - 1,(2)
11 1,2 1,2 1,2 (1),2
12 1,2 - 1,2
13 nd 1,2 1,2
14 nd nd - 1,(2)
Total no. 5 6 7 7
Heterozygosity 4 4 3 5
Allele loss 0 0 0 5
Colonic metastasis
15 1,2 - 1,2 1,2
16 1,2 - (1),2 -
17 1,2 - - 1,2
18 1,2 (1),2 1,(2) -
19 - - 1,2
20 1,2 _ 1,(2) (1),2
21 _ - (1),2 1,(2)
Total no. 7 7 7 7
Heterozygosity 5 1 5 5
Allele loss 0 1 4 2
Homozygosity in the constitutional DNA (non-informative pattern) is indicated as a dash;
where the normal tissue was informative the tumour genotype is shown in the table.
Heterozygosity is indicated by 1,2. The continued presence of the larger allelic restriction
fragment is indicated by 'l' and '2' indicates continued presence ofthe smaller allelic fragment.
Allele loss (deletion or reduction ofintensityofaband) isindicated by(). 'nd' indicates no data.1086 S.F. DING et al.
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Figure 2 Localisation of some of the probes used for
chromosome 5. ECB27 and YN5.48 screen 5q21-22 where APC
gene locates, while AMS8 screens 5q35-qter where allele loss
occurs in HCC.
rhotic patients with different aetiology. It is ofinterest that in
some cases we have been able to compare DNA from lym-
phocytes with that from non-tumorous cirrhotic liver, but as
yet no allele loss (pre-malignant loss) has been detected (data
not shown).
Relatively few chromosome studies have been carried out
on HCC, but investigations on HCC cell lines showed
involvement of chromosome 5, regions p14 and q31-33 in
rearrangement or deletion (Simon et al., 1982; Simon &
Knowles, 1986). Of particular relevance is a chromosome 5
(q34) rearrangment in direct preparations from an HCC
arising in a patient without evidence of HBV infection
(Simon et al., 1990). In other studies (Buetow et al., 1989;
Zhang et al., 1990) frequent allele losses were found on
chromosomes 4 and 16 in both HBV positive and negative
HCC. Tsuda et al. (Tsuda et al., 1990) suggested that LOH
on chromosome 16 represents tumour progression. Our own
study did not show LOH on chromosomes 4q, 16p or 16q.
This could reflect either the difference in probes used or a
difference in the stage of the tumours studied. None of our
patients had extrahepatic tumour spread and all underwent
'potentially curative' resection of the tumours. In agreement
with other workers (Kiechle-Schwarz et al., 1990), we have
found no evidence for allele loss on lip. A literature survey
did not reveal previous screening of the terminal region of 5q
in HCC. In a very recent study (Fujimori et al., 1991) allelic
loss was reported in HBV negative HCC in the region 5q21
(D5S84), but they did not mention the screening of 5q35-
qter.
The comparison of the pattern of LOH on chromosome 5
between patients with non-cirrhotic HCC and patients with
colorectal liver secondaries suggests that the loci are different
in the two types of malignancies. The LOH in carcinoma of
the colon peaks at the region 5q21 -22 while the LOH in
non-cirrhotic HCC is at 5q35 qter. A larger number of sam-
ples needs to be tested to confirm this preliminary finding.
Future work will also aim to identify and characterise the
gene associated with non-cirrhotic HCC.
In conclusion, this study suggests that one of the tumour
suppressor genes in non-cirrhotic HCC could be located on
chromosome 5 and appears to be distinct from the locus of
the familial adenomatous polyposis coli (APC) gene.
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